Degeneration of spared axons following partial white matter lesion: Implications for optic nerve neuropathies

Experimental Neurology

Volumn 153, Issue 1, 1998, Pages 1-7

  Yoles, Eti ^a   Schwartz, Michal ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

CNS trauma; Neuroprotection; Optic nerve; Secondary degeneration

Indexed keywords

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; BRAIN PROTECTION; CONTROLLED STUDY; GRAY MATTER; NERVE FIBER DEGENERATION; NERVE INJURY; NONHUMAN; OPTIC NERVE DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RAT; WHITE MATTER;

EID: 0031707125     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1998.6811     Document Type: Article

References (34)

1. Assia, E., Rosner, M., Belkin, M., Solomon, A., and Schwartz, M. 1989. Temporal parameters of low energy laser irradiation for optimal delay of post-traumatic degeneration of rat optic nerve. Brain Res. 476: 205-212.
2. Basso, D. M., Beattie, M. S., Bresnahan, J. C., Anderson, D. K., Faden, A. I., Gruner, J. A., Holford, T. R., Hsu, C. Y., Noble, L. J., Nockels, R., Perot, P. L. Salzman, S. K., and Young, W. 1996. MASCIS evaluation of open field locomotor scores: Effects of experience and teamwork on reliability. Multicenter Animal Spinal Cord Injury Study. J. Neurotrauma 13: 343-359.
3. Bazan, N. G., Rodriguez, de-Turco-E, B., and Allan, G. 1995. Mediators of injury in neurotrauma: intracellular signal transduction and gene expression. J. Neurotrauma 12: 791-814.
4. Bernert, H., and Turski, L. 1996. Traumatic brain damage prevented by the non-N-methyl-D-aspartate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f] quinoxaline. Proc. Natl. Acad. Sci. USA 93: 5235-5240.
5. Brubaker, R. F. 1996. Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture. Am. J. Ophthalmol. 121: 473-483.
6. Chen, Y., Constantini, S., Trembovler, V., Weinstock, M., and Shohami, E. 1996. An experimental model of closed head injury in mice: Pathophysiology, histopathology, and cognitive deficits. J. Neurotrauma 13: 557-568.
7. Dusart, I., and Schwab, M. E. 1994. Secondary cell death and the inflammatory reaction after dorsal hemisection of the rat spinal cord. Eur. J. Neurosci. 6: 712-724.
8. Duvdevani, R., Rosner, M., Belkin, M., Sautter, J., Sabel, B. A., and Schwartz, M. 1990. Graded crush of the rat optic nerve as a brain injury model: Combining electrophysiological and behavioral outcome. Rest. Neurol. Neurosci. 2: 31-38.
9. Faden, A. I. 1996. Pharmacological treatment of acute traumatic brain injury [editorial comment]. J. Am. Med. Assoc. 276: 569-570.
10. Faden, A. I. 1996. Pharmacological treatment of central nervous system trauma. Pharmacol. Toxicol. 78:12-17.
11. Gean, A. D., Kates, R. S., and Lee, S. 1995. Neuroimaging in head injury. New Horiz. 3: 549-561.
12. Grotta, J. 1995. Why do all drugs work in animals but none in stroke patients? 2. Neuroprotective therapy. J. Intern. Med. 237: 89-94.
13. Hilton, G. 1994. Secondary brain injury and the role of neuroprotective agents. J. Neurosci. Nurs. 26: 251-255.
14. Kimura, H., Meaney, D. F., McGowan, J. C., Grossman, R. I., Lenkinski, R. E., Ross, D. T., McIntosh, T. K., Gennarelli, T. A., and Smith, D. H. 1996. Magnetization transfer imaging of diffuse axonal injury following experimental brain injury in the pig: Characterization by magnetization transfer ratio with histopathologic correlation. J. Comput. Assist. Tomogr. 20: 540-546.
15. Kornhuber, J., Weller, M., Schoppmeyer, K., and Riederer, P. 1994. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J. Neural. Transm. Suppl. 43: 91-104.
16. Liu, D., and McAdoo, D. J. 1993. An experimental model combining microdialysis with electrophysiology, histology, and neurochemistry for exploring mechanisms of secondary damage in spinal cord injury: Effects of potassium. J. Neurotrauma 10: 349-362.
17. Liu, D., Yang, R., Yan, X., and McAdoo, D. J. 1994. Hydroxyl radicals generated in vivo kill neurons in the rat spinal cord: Electrophysiological, histological, and neurochemical results. J. Neurochem. 62: 37-44.
18. Mattson, M. P., and Scheff, S. W. 1994. Endogenous neuroprotection factors and traumatic brain injury: mechanisms of action and implications for therapy. J. Neurotrauma 11: 3-33.
19. McIntosh, T. K. 1993. Novel pharmacologic therapies in the treatment of experimental traumatic brain injury: A review. J. Neurotrauma 10: 215-261.
20. Morgan, J. E. 1994. Selective cell death in glaucoma: Does it really occur? Br. J. Ophthalmol. 78: 875-879.
21. Olanow, C. W. 1993. A radical hypothesis for neurodegeneration [see comments]. Trends Neurosci. 16: 439-444.
22. Pearson, H. E., and Thompson, T. P. 1993. Atrophy and degeneration of ganglion cells in central retina following loss of postsynaptic target neurons in the dorsal lateral geniculate nucleus of the adult cat. Exp. Neurol. 119: 113-119.
23. Quigley, H. A., Sanchez, R. M., Dunkelberger, G. R., L'Hernault, N. L., and Baginski, T. A. 1987. Chronic glaucoma selectively damages large optic nerve fibers. Invest. Ophthalmol. Vis. Sci. 28: 913-920.
24. Schulz, J. B., Matthews, R. T., Henshaw, D. R., and Beal, M. F. 1996. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: Implications for neurodegenerative diseases. Neuroscience 71: 1043-1048.
25. Schumer, R. A., and Podos, S. M. 1994. The nerve of glaucoma! Arch. Ophthalmol. 112: 37-44.
26. Schwartz, M., Hirschberg, D. L., Yoles, E., Solomon, A., Belkin, M., Eitan, S., Lavie, V., Faber-Elman, A., Besserman, P., and Lazarov-Spiegler, O. 1996. Optic nerve disease and injury: Prospects for induction of regeneration. Prog. Ret. Eye Res. 15: 569-580.
27. Siesjo, B. K., Katsura, K., Zhao, Q., Folbergrova, J., Pahlmark, K., Siesjo, P., and Smith, M. L. 1995. Mechanisms of secondary brain damage in global and focal ischemia: A speculative synthesis. J. Neurotrauma 12: 943-956.
28. Smith, D. H., Casey, K., and McIntosh, T. K. 1995. Pharmacologic therapy for traumatic brain injury: experimental approaches. New Horiz. 3: 562-572.
29. Thanos, S., Mey, J., and Wild, M. 1993. Treatment of the adult retina with microglia-suppressing factors retards axotomyinduced neuronal degradation and enhances axonal regeneration in vivo and in vitro. J. Neurosci. 13: 455-466.
30. Trembly, B. 1995. Clinical potential for the use of neuroprotective agents. A brief overview. Ann. NY Acad. Sci. 765:1-20.
31. Yakovlev, A. G., and Faden, A. I. 1995. Molecular biology of CNS injury. J. Neurotrauma 12: 767-777.
32. Yoles, E., Belkin, M., and Schwartz, M. 1996. HU-211, a nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy. J. Neurotrauma 13: 49-57.
33. Yoles, E., Zalish, M., Lavie, V., Duvdevani, R., Ben, B. S., and Schwartz, M. 1992. GM1 reduces injury-induced metabolic deficits and degeneration in the rat optic nerve. Invest. Ophthalmol. Vis. Sci. 33: 3586-3591.
34. Zauner, A., and Bullock, R. 1995. The role of excitatory amino acids in severe brain trauma: opportunities for therapy: A review. J. Neurotrauma 12: 547-554.